Home > Insider Trading > Filing (0001127602-24-008505)

Filing Details

Accession Number:: 0001127602-24-008505
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-05 16:07:01
Reporting Period:: 2024-03-01

Accepted Time:: 2024-03-05 16:07:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1658080	Cedric Francois	C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-01	50,000	$3.76	363,662	No	4	M	Direct
Common Stock	Acquisiton	2024-03-01	200,000	$4.31	563,662	No	4	M	Direct
Common Stock	Disposition	2024-03-01	28,868	$62.21	534,794	No	4	S	Direct
Common Stock	Disposition	2024-03-01	41,704	$62.96	493,090	No	4	S	Direct
Common Stock	Disposition	2024-03-01	62,503	$64.26	430,587	No	4	S	Direct
Common Stock	Disposition	2024-03-01	116,512	$64.92	314,075	No	4	S	Direct
Common Stock	Disposition	2024-03-01	413	$65.68	313,662	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-01	50,000	$0.00	50,000	$3.76
Common Stock	Stock Option (Right to Buy)	Disposition	2024-03-01	200,000	$0.00	200,000	$4.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,840		2026-02-06	No	4	M	Direct
175,538		2027-08-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	532,946	Indirect	Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2)
Common Stock	654,211	Indirect	Indirect Owner (The Cedric Francois Irrevocable Trust of 2023)
Common Stock	300,000	Indirect	Indirect Owner (The Francois Grossi Trust)
Common Stock	234,411	Indirect	Indirect Owner (The Francois-DuBois Educational Trust)

Footnotes

The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.
The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
This transaction was executed in multiple trades at prices ranging from $61.615 - $62.605. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.61 - $63.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $63.665 - $64.645. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $64.6575 - $65.59 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $65.67 - $65.69 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on February 8, 2016 and fully vested.
This option was granted on August 21, 2017 and is fully vested.